A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

Trial Profile

A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-695; PISCES
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 03 Jan 2018 According to an OncoSec Medical media release, positive long-term follow-up data presented at at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017.
    • 03 Jan 2018 According to an OncoSec Medical media release, the company anticipates to complete stage 1 enrollment of this trial in 2018. Preliminary data from PISCES/KEYNOTE-695 will be presented at a medical meeting
    • 14 Dec 2017 According to an OncoSec Medical media release, patient dosing has been initiated for this trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top